Clinical Trial

A Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-1049 in Patients With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is a multicenter, open label, dose exploration/efficacy extension Phase I clinical trial aimed at evaluating the safety, tolerability, pharmacokinetics and efficacy of SHR-1049 injection in patients with advanced solid tumors.
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-17
Trial Details
NCT Number NCT07380334
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions Advanced Solid Tumor
Enrollment 200 participants
Start Date 2026-03-12
Primary Completion 2028-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-16